QUALITATIVE AND OUTCOMES RESEARCH
Article first published online: 02 May 2019
Moderate‐to‐severe atopic dermatitis ( AD ) is a chronic disease characterized by intense, persistent and debilitating itch, resulting in sleep deprivation, signs of anxiety and depression, impaired quality of life and reduced productivity. The Peak Pruritus Numerical Rating Scale ( NRS ) was developed and validated as a single‐item, patient‐reported outcome ( PRO ) of itch severity.
To describe the content validity and psychometric assessment (test–retest reliability, construct validity, known‐groups validity, sensitivity to change) of the Peak Pruritus NRS , and to derive empirically a responder definition to identify adults with a meaningful change in itch.
Content validity was assessed through in‐depth patient interviews. Psychometric assessments used data from phase II b and phase III dupilumab clinical trials and included test–retest reliability, construct validity, known‐groups validity and sensitivity to change in patients with moderate‐to‐severe AD .
Interview participants indicated that the Peak Pruritus NRS was a relevant, clear and comprehensive assessment of itch severity. Peak Pruritus NRS scores showed large, positive correlations with existing PRO measures of itch, and weak or moderate correlations with clinician‐reported measures assessing objective signs of AD . Peak Pruritus NRS score improvements were highly correlated with improvements in other itch PRO s, and moderately correlated with improvements in clinician‐reported measures assessing objective signs of AD . The most appropriate threshold for defining a clinically relevant, within‐person response was ≥ 2–4‐point change in the Peak Pruritus NRS .
The Peak Pruritus NRS is a well‐defined, reliable, sensitive and valid scale for evaluating worst itch intensity in adults with moderate‐to‐severe AD .
|bjd17744-sup-0001-VideoS1.mp4||Video S1 Author video.|
13 Nov 2019
Find out how changing immunosuppressive treatment practices have impacted SCC and BCC cancer risk in organ transplant recipients at https://t.co/wlvY9C1BnB #SCC #BCC #organtransplant #epidemiology https://t.co/tofI5FYhdu
13 Nov 2019
RT The British Association of Dermatologists @HealthySkin4All: We are very excited to be planning the launch of a new open access journal, for which we are now looking for an Editor-in-Chief. Full details and information on how to apply for this role can be found here: https://t.co/42Fego0m99 @BrJDermatol @ced_wiley https://t.co/RAtLL76qpd
12 Nov 2019
Why has there been a significant reduction in the incidences of both SCC and BCC in organ transplant recipients over the past two decades? https://t.co/9LZepIh0V0 #SCC #BCC #organtransplant #epidemiology https://t.co/7mFJDPG3ch
12 Nov 2019
RT The British Association of Dermatologists @HealthySkin4All: There is a need for more economic studies which look at the costs and effectiveness of two or more eczema treatments. These types of studies help inform how healthcare resources are used. https://t.co/jXK2mF2WQe @BrJDermatol @Wiley_Health @eczemasociety https://t.co/r90pWBEcRK